Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell...

Area of Science:

• Oncology
• Genomics
• Immunology

Background:

• TFE3-rearranged renal cell carcinoma (rRCC) is a rare subtype of MiT family translocation renal cell carcinomas.
• Understanding the molecular and immune characteristics of rRCC is crucial for developing targeted therapies.

Purpose of the Study:

• To comprehensively characterize the genomic, transcriptional, and immune landscapes of rRCC.
• To compare these features with clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC).
• To identify potential therapeutic vulnerabilities and strategies for rRCC.

Main Methods:

• Next-generation sequencing (whole transcriptome RNA, 592-gene panel or whole exome DNA) was performed on rRCC (N=20), pRCC (N=20), and ccRCC (N=392) samples.
• Genomic alterations, mutation rates, and gene expression patterns were analyzed and compared across subtypes.
• Immune cell infiltration (M1 macrophages) and immune marker expression (PD-L1) were assessed.

Main Results:

• Patients with rRCC were significantly younger and more frequently female compared to pRCC and ccRCC.
• rRCC exhibited distinct genomic profiles with sparse mutations, unlike the high VHL and PBMR1 mutation rates in ccRCC.
• rRCC showed a colder immune microenvironment with less M1 macrophages but a higher prevalence of PD-L1 positivity compared to pRCC and ccRCC.
• Gene set enrichment analysis indicated that rRCC are enriched in genes related to oxidative phosphorylation.

Conclusions:

• TFE3-rearranged renal cell carcinoma possesses a unique molecular and immune profile.
• The higher PD-L1 expression in rRCC, despite a colder immune microenvironment, suggests potential efficacy of immune checkpoint inhibitor therapy.
• Further research into the specific co-alterations and immune interactions in rRCC is warranted.